Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Additionally, atezolizumab, Atreca, begun, bivalent, bound, broadly, called, colorectal, confirmed, cycle, demonstrated, density, eleven, engrafted, environmental, format, heavily, independently, ipilimumab, kidney, kill, lead, lower, microsatellite, modularity, Monjuvi, mouse, mutually, National, nivolumab, ovarian, overexpressed, poor, preferentially, pretreated, progressive, RCC, reduction, slower, sparing, stable, strong, tissue, underexplored, understanding, variety
Filing tables
Filing exhibits
Related press release
Associated XNCR transcripts
XNCR similar filings
Filing view
External links